secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001062822-23-000019
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon amends Oxford loan: third tranche raised to $75M, adds minimum cash covenant
--------------------------------------------------------------------------------

- Third tranche increased from $50M to $75M; fourth tranche reduced to $25M (subject to Oxford's consent).
- New minimum cash covenant effective after third tranche funding; unused fee if full tranche not drawn.
- Revenue covenant tied to sotagliflozin net product revenue milestones after FDA approval.
- Minimum cash test dates deferred based on achieving net-proceeds milestones from partnering or financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000019/0001062822-23-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000019/lxrx-20230501.htm
  HTML page:      https://secwatch.observer/filing/0001062822-23-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer